There is still a great deal of work to be done, but today we celebrate thanks in no small part to the sarcoma investigators of the @NCItreatment’s ETCTN, @bvantine1, @thenasheffect, @geosullivanc, @NaokoTakebe, #AliceChen, #JamesDoroshow & many others! https://t.co/3yVHBzeYk4

Thanks to all the investigators and patients who contributed! We were fortunate to work with @genentech & @FDAOncology to obtain FDA approval for this rare population. Approved for patients aged 2 & above thanks to @NCI_CCR_PedOnc & @NCItreatment https://t.co/3yVHBzfw9C

This trial was supported by @genentech through a collaborative research and dev agreement (CRADA) with @theNCI, and follows research by the @NCItreatment suggesting a benefit of immunotherapy! This was the first trial we initiated under the CRADA. https://t.co/3yVHBzeYk4

We found that 37% of treated patients exhibited a durable and sustained investigator-assessed response, offering meaningful benefit to patients and changing the treatment paradigm for this ultra-rare sarcoma, primarily affecting adolescents & young adults. https://t.co/3yVHBzeYk4

Excited to present the results of the @NCICTEP_ClinRes-sponsored trial, 10005, for patients with Alveolar Soft Part Sarcoma (#ASPS) who were treated with the #PDL1 inhibitor, atezolizumab in the @NEJM this week: https://t.co/3yVHBzeYk4